Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 67
- 试验地点
- 2
- 主要终点
- Proportion of patients for whom Oraquick HCV Antibody Test accurately diagnosed anti-HCV status
研究概览
简要总结
Rapid tests are increasingly used in medical practice, notably to screen for HIV. Their use has been associated with a faster linkage to care and lower rates of loss to follow up. Rapid tests are also well accepted by patients and clinicians.
No rapid test is currently approved in Canada for screening of hepatitis C. Hepatitis C diagnosis is done through based on blood testing and the screening algorithm may require up to 3 visits to clarify the hepatitis C status.
The Oraquick HCV test is a rapid test done on blood or saliva that can replace the first step of the regular screening algorithm. With this test the initial screening and the confirmation test can be done in one visit.
The primary endpoint of this pilot-project is to evaluate clinical characteristics of Oracquick HCV (sensitivity, specificity, positive and negative predictive values) and to compare them to those of the standard screening algorithm in a population of active or ex-users of injected drugs. The project also intend to evaluate if the rapid test can reduce the rates of loss to follow up and increase the linkage to hepatitis C specialized care. This last endpoint will be evaluated through phone call follow up 6 months after the screening.
One hundred and fifty patients will be included. Half will be tested with the standard algorithm and the Oraquick HCV test (group A) and half will be tested only with the standard algorithm.
Results of group A will be used to determine the clinical characteristics of Oraquick HCV. Results of groups A and B will be used to evaluate rates of loss to follow up, costs avoided by the use of the rapid test and linkage to care of infected patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Indication of hepatitis C screening
- •Active or ex-injection drug user
排除标准
- •Known hepatitis C infection
- •Unknown HIV status and patient refusing to HIV testing
结局指标
主要结局
Proportion of patients for whom Oraquick HCV Antibody Test accurately diagnosed anti-HCV status
时间窗: Patients will be followed for an expected average of 6 weeks
Oraquick HCV Antibody test will be compared to a composite goldstandard: * If both the Oraquick test and the standard test are negative, the results will be considered as a true negative. * If both the Oraquick test and the standard test are positive, the results will be considered as a true positive. * If the tests are discordant, HCV RNA testing will be performed. If HCV RNA is positive, the result of the test who predicted the positive result will be a true positive and the result of the other test will be a false negative. If the HCV RNA is negative, the result of the standard test will be considered as the true value (either positive or negative).
次要结局
- Loss to follow up(3 months)
- Satisfaction(15 minutes)
- Linkage to care(6 months)
- Avoided costs(6 months)
研究者
Valérie Martel-Laferrière
MD, MS, FRCPC
Centre hospitalier de l'Université de Montréal (CHUM)